MOM

Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and commercializing
diagnostic tests and risk assessment technologies for unmet clinical needs,
today provides an update on current initiatives. 


Master Investor Technology Showcase

The Company is pleased to announce that it will be a featured, new technology
exhibitor at the upcoming Master Investor Conference to be held Saturday, April
26, 2014 in London, England. The conference will provide a unique profile for
Miraculins' technologies within the UK investment community by showcasing and
demonstrating the Scout DS(R) Non-Invasive Diabetes Screening Test and the
PreVu(R) Non-Invasive Skin Cholesterol Test to conference attendees. 


Master Investor is regarded as the leading investor show in the UK, uniting
highly respected speakers and exhibiting companies from a broad range of
sectors. This year's Master Investor is expected to draw an audience of well
over 3,500 motivated investors, brokers and industry analysts who come to
research, analyze and invest. 


Scout DS(R) - USFDA Pre-Submission Process

On December 23, 2013, Miraculins announced it had filed pre-submission
documentation with the USFDA (United States Food and Drug Administration)
towards securing Scout DS(R) marketing clearance in the United States.
Miraculins met with USFDA on March 19, 2014 to discuss the Company's
Pre-Submission document. Scout DS(R) performance, reported in recently published
clinical studies, was discussed at the meeting, as well as the proposed intended
use of the device. USFDA provided helpful advice to Miraculins and requested
additional information in order to issue guidance regarding appropriate
regulatory pathways for the product. The additional information, in the form of
a Pre-Submission Supplement, is expected to be sent to the USFDA by the end of
April. Scout DS(R) has received regulatory clearance in Canada and throughout
the European Union. 


Scout DS(R) - Chinese Distribution Agreement Negotiations 

On January 31, 2014, Miraculins announced that it had executed a term sheet
("Term Sheet") with Cachet Pharmaceutical Co., Ltd. ("Cachet") to appoint Cachet
as the exclusive Chinese distributor for the Scout DS(R) Non-Invasive Diabetes
Screening Test. The Term Sheet established the principal terms and conditions of
the proposed distribution agreement (the "Agreement") and provided Cachet with
an exclusive period of ninety days within which to finalize definitive
documentation. The parties continue to advance discussions and make progress
towards finalizing the definitive documentation. 


The completion of the definitive documentation and the execution of the
Agreement remain subject to all necessary contractual, regulatory and corporate
approvals of both Miraculins and Cachet and the completion of satisfactory due
diligence. The Term Sheet provisions are not legally binding except for
provisions regarding exclusivity, confidentiality and governing law. There is no
assurance that the parties will enter into definitive documentation or execute
the Agreement contemplated by the Term Sheet.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


Scout DS(R) and PreVu(R) are registered trademarks of Miraculins Inc. All Rights
Reserved. 2014.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com

Miraculins Inc. (TSXV:MOM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Miraculins Inc. (TSXV:MOM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024